Nutritional science for mind health products
DSM Nutritional Products
Just last month the company announced its probiotic will be available in the Czech and Greek markets.
The move reinforces the potential for probiotic companies to use their strains and formulas across the world, and the popularity of the friendly bacteria among consumers.
The launch is being formally announced at the Chilean Congress of Gastroenterology held this week.
Further expansion in India is expected later this year, with a different partner.
Indeed, over the next few years growth in the market is expected to increase. The probiotic supplement market is growing worldwide. In Europe, it is currently worth the most in Italy. The Italians' belief in the effectiveness of probiotics at boosting gut health has driven the economy to $310m (€219m) in just five years, according to Euromonitor.
By 2011 the Italian market is expected to grow by 28 per cent to $396m (€279m) and North America could experience a boom of 74 per cent, rising from 2006's $293m (€207m) to $509m (€359m).
In the last two years - since lp299v was launched in the US - the strain is now available in South Africa, France, UK and Finland.
Lp299v is distributed under different trade marks by Rosell's partners, Bion Transit is the name of the supplement in France and Chile.
In Czech Republic, the partner is Rougier, in Greece Smart Intermed, and Nutrilida in South Africa.
Sylvie Morin, sales and marketing director for the Americas, said: "Today, Bion Transit has became the leading probiotic targeting bloating and gas reduction in the French market, and we are confident that our Lp299v probiotic is a good candidate to penetrate the South American market as it constitutes a natural and clinically proven solution in supporting irritable bowel syndrome sufferers."
Irritable Bowel Syndrome (IBS) is the most common functional disorder of the gastrointestinal tract, characterized by abdominal pain, bloating and irregular bowel function.
It affects an estimated 10 to 20 per cent of the western world's population.
There has been documented evidence showing the potential of Lp299v's positive impact on IBS patients.
Institut Rosell-Lallemand said a placebo-controlled randomized study had shown intestinal discomfort was improved by up to 95 per cent in patients, compared to 15 per cent with placebo, while abdominal pain and bloating were also significantly decreased.